KISUNLA DIN 02567725
Health Canada record
| Active ingredient(s) | DONANEMAB 17.5 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION; SCHEDULE D |
| Class | Human |
| ATC | N06DX05 DONANEMAB |
| Original market date | 03-Jul-2026 |
| Current status date | 03-Jul-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Eli Lilly Canada Inc. — licence 100164, currently licensed, last inspection rating C (2026-03-24).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37446 | 2026-04-30 | New Drug Submission (NDS) |